Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US

References

• Groot KoerkampB, Myriam HuninkMG, StijnenT, WeinsteinMC. Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. Health Econ. 2006;15(4):383–392.
   PubMed Web of Science ®Google Scholar
• Groot KoerkampB, WeinsteinMC, StijnenT, Heijenbrok-KalMH, HuninkMG. Uncertainty and patient heterogeneity in medical decision models. Med Decis Making. 2010;30(2):194–205.
   PubMed Web of Science ®Google Scholar
• FauciAS, JohnstonMI, DieffenbachCW, BurtonDR, HammerSM, HoxieJA, et al.HIV vaccine research: the way forward. Science. 2008;321(5888):530–532.
   PubMed Web of Science ®Google Scholar
• HighKP, Brennan-IngM, CliffordDB, CohenMH, CurrierJ, DeeksSG, et al.HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012;60:S1–S18.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Challenges in Clinical Research. Transforming clinical research in the United States: challenges and opportunities: workshop summary. Washington, DC: Available from: http://www.ncbi.nlm.nih.gov/books/NBK50888/. Accessed July 24, 2015National Academics Press (US); 2015.
   Google Scholar
• JervisC. HIV/AIDS clinical trials network to take on new research priorities under severe funding constraints. 2011;. Available from: http://www.treatmentactiongroup.org/tagline/2011/winter/clinical-trials-network-new-priorities. Accessed July 24, 2015.
   Google Scholar
• LopesG. NIH cuts ACTG AIDS research funding. 2006;. Available from: http://www.natap.org/2007/newsUpdates/010207_17.htm. Accessed July 24, 2015.
   Google Scholar
• SaxPE. Generic lamivudine has arrived. 2015;. NEJM Journal Watch Blogs; Available from: http://blogs.jwatch.org/hiv-id-observations/index.php/generic-lamivudine-has-arrived/2012/01/22/. Accessed July 24, 2015..
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 2015;. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed June 6, 2015.
   Google Scholar
• CutlerDM, RosenAB, VijanS. The value of medical spending in the United States, 1960-2000. N Engl J Med. 2006;355(9):920–927.
   PubMed Web of Science ®Google Scholar
• GopalappaC, FarnhamPG, HutchinsonAB, SansomSL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61(1):99–105.
   PubMed Web of Science ®Google Scholar
• BraithwaiteRS, MeltzerDO, KingJTJr, LeslieD, RobertsMS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?Med Care. 2008;46(4):349–356.
   PubMed Web of Science ®Google Scholar
• NeumannPJ, CohenJT, WeinsteinMC. Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• PaltielAD, WeinsteinMC, KimmelAD, SeageGR3rd, LosinaE, ZhangH, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–595.
   PubMed Web of Science ®Google Scholar
• WalenskyRP, SaxPE, NakamuraYM, WeinsteinMC, PeiPP, FreedbergKA, et al.Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84–92.
   PubMed Web of Science ®Google Scholar
• GallantJE, StaszewskiS, PozniakAL, DeJesusE, SuleimanJM, MillerMD, et al.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.
   PubMed Web of Science ®Google Scholar
• LennoxJL, DeJesusE, LazzarinA, PollardRB, MadrugaJV, BergerDS, et al.Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796–806.
   PubMed Web of Science ®Google Scholar
• MolinaJM, CahnP, GrinsztejnB, LazzarinA, MillsA, SaagM, et al.Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238–246.
   PubMed Web of Science ®Google Scholar
• SaxPE, DeJesusE, MillsA, ZolopaA, CohenC, WohlD, et al.Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439–2448.
   PubMed Web of Science ®Google Scholar
• AlthoffKN, GangeSJ, KleinMB, BrooksJT, HoggRS, BoschRJ, et al.Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–1520.
   PubMed Web of Science ®Google Scholar
• Personal communication with Dr. Keri Althoff on 12 May 2013.
   Google Scholar
• RED BOOK Online 2014. Micromedex Solutions. Truven Health Analytics Inc. Available from:http://redbook.solutions.aap.org/book.aspx?bookid=1484 Accessed September 18, 2015.
   Google Scholar
• DaarES, TierneyC, FischlMA, SaxPE, MollanK, BudhathokiC, et al.Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445–456.
   PubMed Web of Science ®Google Scholar
• JohnsonM, GrinsztejnB, RodriguezC, CocoJ, DeJesusE, LazzarinA, et al.Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19(7):685–694.
   PubMed Web of Science ®Google Scholar
• JohnsonM, GrinsztejnB, RodriguezC, CocoJ, DeJesusE, LazzarinA, et al.96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711–718.
   PubMed Web of Science ®Google Scholar
• RiddlerSA, HaubrichR, DiRienzoAG, PeeplesL, PowderlyWG, KlingmanKL, et al.Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–2106.
   PubMed Web of Science ®Google Scholar
• The North American AIDS Cohort Collaboration on Research and Design. NA-ACCORD dossier. 2014;. Available from: http://statepiaps.jhsph.edu/naaccord/dossier/NA-ACCORD_Dossier_2014_0404.pdf. Accessed July 24, 2015..
   Google Scholar
• BriggsAH, ClaxtonK, SculpherM. Decision Modelling for Health Economic Evaluation. New York: Oxford University Press; 2006.
   Google Scholar
• HuninkMG, WeinsteinMC, WittenbergE, DrummondMF, PliskinJS, WongJB, et al.Heterogeneity and uncertainty. Decision Making in Health and Medicine. 2nd edn. Cambridge, UK: Cambridge University Press; 2014.
   Google Scholar
• SteutenL, van de WeteringG, Groothuis-OudshoornK, ReteV. A systematic and critical review of the evolving methods and applications of value of information in academia and practice. Pharmacoeconomics. 2013;31(1):25–48.
   PubMed Web of Science ®Google Scholar
• RothJA, EtzioniR, WatersTM, PettingerM, RossouwJE, AndersonGL, et al.Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med. 2014;160(9):594–602.
   PubMed Web of Science ®Google Scholar
• MyersE, McBroomAJ, ShenL, PoseyRE, GrayR, SandersGD. Value-of-Information Analysis for Patient-Centered Outcomes Research Prioritization. Durham, NC: Duke Evidence-based Practice Center; 2012.
   Google Scholar
• PaltielAD, GoldieSJ, LosinaE, WeinsteinMC, SeageGR3rd, KimmelAD. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis. 2001;32(5):783–793.
   PubMed Web of Science ®Google Scholar
• LorenzanaSB, HughesMD, GrinsztejnB, CollierAC, LuzPM, FreedbergKA, et al.Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS. 2012;26(9):1083–1093.
   PubMed Web of Science ®Google Scholar
• NachegaJB, ParientiJJ, UthmanOA, GrossR, DowdyDW, SaxPE, et al.Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297–1307.
   PubMed Web of Science ®Google Scholar
• EichlerHG, KongSX, GerthWC, MavrosP, JonssonB. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?Value Health. 2004;7(5):518–528.
   PubMed Web of Science ®Google Scholar
• SiebertU, RochauU, ClaxtonK. When is enough evidence enough? Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. Z Evid Fortbild Qual Gesundhwes. 2013;107(9-10):575–584.
   PubMedGoogle Scholar
• WillanAR, EckermannS. Value of information and pricing new healthcare interventions. Pharmacoeconomics. 2012;30(6):447–459.
   PubMed Web of Science ®Google Scholar
• FrewEJ, WhynesDK, WolstenholmeJL. Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats. Med Decis Making. 2003;23(2):150–159.
   PubMed Web of Science ®Google Scholar
• GrosseSD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–178.
   PubMedGoogle Scholar
• HirthRA, ChernewME, MillerE, FendrickAM, WeissertWG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332–342.
   PubMed Web of Science ®Google Scholar
• KingJTJr, TsevatJ, LaveJR, RobertsMS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making. 2005;25(6):667–677.
   PubMed Web of Science ®Google Scholar
• ClotetB, FeinbergJ, van LunzenJ, Khuong-JossesMA, AntinoriA, DumitruI, et al.Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222–2231.
   PubMed Web of Science ®Google Scholar
• CohenMS, ChenYQ, McCauleyM, GambleT, HosseinipourMC, KumarasamyN, et al.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2008;. Avaliable from: https://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL001226.pdf. Accessed June 16, 2015.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012;. https://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL003093.pdf. Accessed June 16, 2015.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2014;. https://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL003390.pdf. Accessed June 16, 2015.
   Google Scholar
• RaffiF, RachlisA, StellbrinkHJ, HardyWD, TortiC, OrkinC, et al.Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves new drug to treat HIV infection. 2013;. Avaliable from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm. Accessed June 16, 2015.
   Google Scholar
• U.S. Food and Drug Administration. Approval of new fixed dose combination, TRIUMEQ (abacavir sulfate, dolutegravir, lamivudine). 2014;. Avaliable from: http://content.govdelivery.com/accounts/USFDA/bulletins/cb6dfa/. Accessed June 16, 2015.
   Google Scholar
• WalmsleySL, AntelaA, ClumeckN, DuiculescuD, EberhardA, GutierrezF, et al.Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antiretroviral treatment as prevention (TasP) of HIV and TB. 2012;. Avaliable from: http://whqlibdoc.who.int/hq/2012/WHO_HIV_12_eng.pdf?ua = 1. Accessed June 8, 2015.
   Google Scholar
• SaxPE, TierneyC, CollierAC, FischlMA, MollanK, PeeplesL, et al.Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230–2240.
   PubMed Web of Science ®Google Scholar
• GoldieSJ, YazdanpanahY, LosinaE, WeinsteinMC, AnglaretX, WalenskyRP, et al.Cost-effectiveness of HIV treatment in resource-poor settings - the case of Côte d'Ivoire. N Engl J Med. 2006;355(11):1141–1153.
   PubMed Web of Science ®Google Scholar